Drug:
Reaction: INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION
20260101 - 20261231
No. 301 - 400
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 301 | 26916932 |
US |
64 | 1 |
Skin fissures, Dry skin, Skin exfoliation, Pruritus, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, GEMFIBROZIL, NEBIVOLOL, NEBIVOLOL HYDROCHLORIDE, NIACIN, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, EVOLOCUMAB, ROSUVASTATIN CALCIUM, SERTRALINE HYDROCHLORIDE, |
||||
| 302 | 26916994 |
BR |
2 | |
Uterine disorder, Inappropriate schedule of product administration, |
||||
LENALIDOMIDE, |
||||
| 303 | 26917161 |
US |
82 | |
Inappropriate schedule of product administration, Blood pressure abnormal, Cardiac disorder, Urinary tract infection, |
||||
MITOMYCIN, MITOMYCIN, MITOMYCIN, |
||||
| 304 | 26917190 |
US |
69 | 1 |
Dyspnoea, Cough, Product dose omission issue, Inappropriate schedule of product administration, Device delivery system issue, Device use error, |
||||
| 305 | 26917274 |
US |
75 | 1 |
Inappropriate schedule of product administration, |
||||
INSULIN GLARGINE, |
||||
| 306 | 26917297 |
US |
5 | 1 |
Inappropriate schedule of product administration, |
||||
ALGLUCOSIDASE ALFA, METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE, EPINEPHRINE, ADRENALINUM, BACTERIOSTATIC WATER, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, DIPHENHYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE, LIDOCAINE AND PRILOCAINE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, |
||||
| 307 | 26917312 |
US |
2 | |
Eye discharge, Periorbital swelling, Ocular hyperaemia, Eye pruritus, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 308 | 26917361 |
US |
50 | 2 |
Weight loss poor, Drug ineffective, Hunger, Inappropriate schedule of product administration, |
||||
| 309 | 26917518 |
US |
2 | |
Gastrointestinal disorder, Inappropriate schedule of product administration, Abdominal pain, |
||||
TIRZEPATIDE, |
||||
| 310 | 26917628 |
US |
63 | 2 |
Neoplasm malignant, Inappropriate schedule of product administration, |
||||
VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, |
||||
| 311 | 26917634 |
US |
58 | 2 |
Cardiac arrest, Inappropriate schedule of product administration, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 312 | 26917642 |
CA |
34 | 1 |
Seizure like phenomena, Dyskinesia, Inappropriate schedule of product administration, |
||||
ARIPIPRAZOLE ORALLY DISINTEGRATING, ARIPIPRAZOLE, ARIPIPRAZOLE ORAL, |
||||
| 313 | 26917691 |
US |
2 | |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, |
||||
| 314 | 26917721 |
39 | 2 | |
Sinusitis, Inappropriate schedule of product administration, |
||||
REPOSITORY CORTICOTROPIN, |
||||
| 315 | 26917877 |
CN |
55 | 2 |
Myelosuppression, Inappropriate schedule of product administration, Inappropriate schedule of product administration, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, CARBOPLATIN, CARBOPLATIN, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), |
||||
| 316 | 26917881 |
CA |
42 | |
Colitis ulcerative, Heart rate increased, Weight increased, Dizziness, Inappropriate schedule of product administration, Underdose, Suspected off label use, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, PREDNISONE, CALCIUM, PANTOPRAZOLE, |
||||
| 317 | 26917889 |
US |
52 | |
Device deployment issue, Inappropriate schedule of product administration, |
||||
USTEKINUMAB, USTEKINUMAB, |
||||
| 318 | 26917930 |
US |
83 | 2 |
Inappropriate schedule of product administration, |
||||
BIMEKIZUMAB, |
||||
| 319 | 26917932 |
CA |
52 | |
Haematochezia, Abdominal pain, Diarrhoea, Off label use, Inappropriate schedule of product administration, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB, VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE, TEMAZEPAM, |
||||
| 320 | 26917937 |
CO |
9 | 2 |
Seizure, Sleep apnoea syndrome, Inappropriate schedule of product administration, Overdose, |
||||
LACOSAMIDE, LACOSAMIDE, LEVETIRACETAM, VIGABATRIN, TOPIRAMATE, CLOBAZAM, |
||||
| 321 | 26917960 |
US |
75 | |
Inappropriate schedule of product administration, |
||||
MITOMYCIN, MITOMYCIN, MITOMYCIN, |
||||
| 322 | 26917986 |
US |
||
Joint injury, Inappropriate schedule of product administration, Product use in unapproved indication, |
||||
TOBRAMYCIN, |
||||
| 323 | 26918120 |
US |
||
Drooling, Tremor, Sedation, Inappropriate schedule of product administration, |
||||
PALIPERIDONE PALMITATE, PALIPERIDONE PALMITATE, PALIPERIDONE PALMITATE, |
||||
| 324 | 26918128 |
US |
76 | 2 |
Death, Inappropriate schedule of product administration, |
||||
DEUTETRABENAZINE, CLONAZEPAM, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, BRIVARACETAM, ESCITALOPRAM, ESCITALOPRAM OXALATE, ESCITSLOPRAM, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, RAMIPRIL, |
||||
| 325 | 26918233 |
US |
1 | |
Inappropriate schedule of product administration, |
||||
BIMEKIZUMAB, |
||||
| 326 | 26918302 |
US |
65 | 2 |
Depressed level of consciousness, Dizziness, Vertigo, Medication error, Inappropriate schedule of product administration, |
||||
BRIMONIDINE TARTRATE, |
||||
| 327 | 26918446 |
US |
52 | 2 |
Crohn^s disease, Inappropriate schedule of product administration, |
||||
CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, |
||||
| 328 | 26918552 |
US |
1 | |
Inappropriate schedule of product administration, |
||||
INSULIN GLARGINE, |
||||
| 329 | 26918597 |
US |
1 | |
Product dose omission issue, Inappropriate schedule of product administration, |
||||
FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, |
||||
| 330 | 26918676 |
US |
71 | 1 |
Poor quality product administered, Inappropriate schedule of product administration, Wrong technique in product usage process, Product physical issue, |
||||
ICOSAPENT ETHYL, |
||||
| 331 | 26918755 |
CA |
57 | 1 |
Tachycardia, Myocardial infarction, Inappropriate schedule of product administration, |
||||
FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, UMECLIDINIUM, UMECLIDINIUM, ALBUTEROL SULFATE, MONTELUKAST SODIUM, |
||||
| 332 | 26918851 |
US |
63 | 2 |
Inappropriate schedule of product administration, Device issue, |
||||
BIMEKIZUMAB, |
||||
| 333 | 26918958 |
US |
1 | |
Cardiac failure, Cough, Wheezing, Wrong technique in device usage process, Wrong technique in product usage process performed in error, Product storage error, Product dose omission issue, Inappropriate schedule of product administration, |
||||
ALBUTEROL SULFATE, |
||||
| 334 | 26919084 |
US |
22 | |
Dry skin, Inappropriate schedule of product administration, |
||||
ISOTRETINOIN, |
||||
| 335 | 26919143 |
US |
2 | |
Photosensitivity reaction, Inappropriate schedule of product administration, |
||||
ACOLTREMON, CYCLOSPORINE OPHTHALMIC SOLUTION, |
||||
| 336 | 26919185 |
US |
1 | |
Aphonia, Feeling jittery, Restlessness, Inappropriate schedule of product administration, |
||||
ACOLTREMON, |
||||
| 337 | 26919208 |
US |
50 | 2 |
Eye irritation, Eye pain, Inappropriate schedule of product administration, |
||||
ACOLTREMON, CETIRIZINE HYDROCHLORIDE, |
||||
| 338 | 26919220 |
US |
61 | 2 |
Dysgeusia, Inappropriate schedule of product administration, |
||||
ACOLTREMON, TRIAMTERENE CAPSULES, TRIAMTERENE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, |
||||
| 339 | 26919354 |
US |
63 | 2 |
Eye irritation, Drug ineffective, Inappropriate schedule of product administration, |
||||
ACOLTREMON, CARVEDILOL, |
||||
| 340 | 26919357 |
US |
2 | |
Eye irritation, Incorrect dose administered, Inappropriate schedule of product administration, |
||||
ACOLTREMON, DOXYCYCLINE HYCLATE, DOXYCYCLINE, DOXYCLYCLINE HYCLATE, LANSOPRAZOLE, THYROID, IODIUM,BADIAGA,FUCUS VESICULOSUS,CALCAREAARSENICUM IODATUM, THYROIDINUM,CARBONICA,PULSATILLA,BARYTA CARBONICA,, |
||||
| 341 | 26919473 |
CA |
86 | 2 |
Pneumonia, Death, Inappropriate schedule of product administration, |
||||
RITUXIMAB, RITUXIMAB, RITUXIMAB, |
||||
| 342 | 26919552 |
US |
71 | 2 |
Eye pruritus, Eye irritation, Inappropriate schedule of product administration, |
||||
ACOLTREMON, ALBUTEROL SULFATE, ALBUTEROL, ARIPIPRAZOLE ORALLY DISINTEGRATING, ARIPIPRAZOLE, ARIPIPRAZOLE ORAL, CARISOPRODOL, CITALOPRAM, CITALOPRAM HYDROBROMIDE, EZETIMIBE, FOLIC ACID, LAMOTRIGINE, OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN, PREGABALIN, SUCRALFATE, SUCRALFATE ORAL SUSPENSION, SUCRALFATE ORAL, TRIAZOLAM, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, |
||||
| 343 | 26919641 |
US |
77 | 2 |
Epistaxis, Periorbital swelling, Inappropriate schedule of product administration, |
||||
ACOLTREMON, ERGOCALCIFEROL, DULOXETINE HYDROCHLORIDE, DULOXETINE, MAGNESIUM OXIDE, TIZANIDINE, |
||||
| 344 | 26919720 |
US |
58 | 2 |
Periorbital pain, Ocular discomfort, Eye irritation, Inappropriate schedule of product administration, |
||||
ACOLTREMON, |
||||
| 345 | 26919740 |
US |
79 | 1 |
Dry eye, Inappropriate schedule of product administration, |
||||
ACOLTREMON, ATENOLOL, EZETIMIBE, FENOFIBRATE, ROSUVASTATIN, TELMISARTAN, |
||||
| 346 | 26919762 |
US |
84 | 2 |
Ocular hyperaemia, Drug ineffective, Eye irritation, Inappropriate schedule of product administration, |
||||
ACOLTREMON, ACOLTREMON, THIAMINE HYDROCHLORIDE, RIBOFLAVIN 5 PHOSPHATE SODIUM, DEXPANTHENOL AND NIACINAMIDE, CALCIUM, LATANOPROST, PANTOPRAZOLE, DENOSUMAB, ERGOCALCIFEROL, |
||||
| 347 | 26919815 |
US |
63 | 2 |
Drug ineffective, Inappropriate schedule of product administration, |
||||
ACOLTREMON, HYDROXYCHLOROQUINE, VALSARTAN, VALSARTAN ORAL, |
||||
| 348 | 26919870 |
US |
65 | 2 |
Drug ineffective, Inappropriate schedule of product administration, |
||||
LOTEPREDNOL ETABONATE, ACOLTREMON, BENZONATATE, CYCLOSPORINE, CLONAZEPAM, LEVALBUTEROL HYDROCHLORIDE, MECLIZINE HCL 12.5 MG, MECLIZINE HCL 25 MG, MECLIZINE HYDROCHLORIDE, MECLIZINE, MECLIZINE HCL 25MG, MECLIZINE HCL 12.5MG, MIRABEGRON, MONTELUKAST, MUPIROCIN, MUPIROCIN CALCIUM, NAPROXEN, NAPROXEN SODIUM, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, TIZANIDINE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, |
||||
| 349 | 26919876 |
US |
74 | 2 |
Eye irritation, Product dose omission issue, Inappropriate schedule of product administration, |
||||
ACOLTREMON, ACOLTREMON, LOSARTAN, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, |
||||
| 350 | 26920008 |
US |
2 | |
Inappropriate schedule of product administration, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, BUDESONIDE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, LOSARTAN POTASSIUM, LOSARTAN, MONTELUKAST, ROSUVASTATIN, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, |
||||
| 351 | 26920210 |
US |
66 | 2 |
Eye irritation, Inappropriate schedule of product administration, |
||||
ACOLTREMON, AMLODIPINE, BUPROPION, ROSUVASTATIN, IRON, LINACLOTIDE, LOSARTAN, ESOMEPRAZOLE MAGNESIUM, AMLODIPINE BESYLATE, FAMOTIDINE, ALPRAZOLAM, |
||||
| 352 | 26920324 |
US |
77 | 2 |
Eye swelling, Eye irritation, Eye pain, Inappropriate schedule of product administration, Multiple use of single-use product, |
||||
ACOLTREMON, CYCLOSPORINE OPHTHALMIC SOLUTION, ERGOCALCIFEROL, |
||||
| 353 | 26920521 |
US |
61 | 2 |
Eye pain, Inappropriate schedule of product administration, |
||||
ACOLTREMON, |
||||
| 354 | 26920538 |
US |
83 | 1 |
Drug ineffective, Inappropriate schedule of product administration, |
||||
ACOLTREMON, LATANOPROST, LOSARTAN, MIRABEGRON, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, PREDNISONE, ROSUVASTATIN, |
||||
| 355 | 26920721 |
US |
2 | |
Road traffic accident, Inappropriate schedule of product administration, Intentional product use issue, |
||||
ACOLTREMON, |
||||
| 356 | 26920791 |
US |
70 | 2 |
Eye irritation, Inappropriate schedule of product administration, |
||||
ACOLTREMON, |
||||
| 357 | 26920905 |
US |
71 | 2 |
Ocular discomfort, Inappropriate schedule of product administration, |
||||
ACOLTREMON, ACOLTREMON, FISH OIL, HYDROCHLOROTHIAZIDE, LOSARTAN, CYCLOSPORINE OPHTHALMIC SOLUTION, |
||||
| 358 | 26921089 |
US |
82 | |
Inappropriate schedule of product administration, |
||||
NEMOLIZUMAB-ILTO, FUROSEMIDE, FISH OIL, |
||||
| 359 | 26921098 |
US |
81 | |
Acute kidney injury, Inappropriate schedule of product administration, |
||||
MITOMYCIN, |
||||
| 360 | 26921149 |
US |
||
Inappropriate schedule of product administration, |
||||
GLECAPREVIR AND PIBRENTASVIR, |
||||
| 361 | 26921253 |
BR |
||
Pancytopenia, Inappropriate schedule of product administration, |
||||
DARATUMUMAB, LENALIDOMIDE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, |
||||
| 362 | 26909611 |
US |
44 | 2 |
Feeling abnormal, Inappropriate schedule of product administration, |
||||
FREMANEZUMAB-VFRM, |
||||
| 363 | 26909664 |
US |
54 | 1 |
Carpal tunnel syndrome, Cyst, Rash, Inappropriate schedule of product administration, |
||||
UPADACITINIB, UPADACITINIB, UPADACITINIB, |
||||
| 364 | 26909738 |
68 | 2 | |
Lower respiratory tract infection, Transient ischaemic attack, Off label use, Inappropriate schedule of product administration, |
||||
USTEKINUMAB, |
||||
| 365 | 26909739 |
GB |
56 | |
Defaecation urgency, Gastrointestinal obstruction, Diarrhoea, Product quality issue, Symptom recurrence, Inappropriate schedule of product administration, Loss of therapeutic response, Treatment noncompliance, Therapy cessation, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 366 | 26909788 |
US |
||
Inappropriate schedule of product administration, |
||||
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, |
||||
| 367 | 26909838 |
CL |
51 | 2 |
Osteonecrosis, Metastasis, Neutrophil count decreased, Breast cancer, Malignant neoplasm progression, Rectal cancer, Second primary malignancy, Metastases to bone, Bone pain, Pain, Back pain, Illness, Sinus bradycardia, Full blood count abnormal, Mean cell volume increased, Mean cell haemoglobin increased, Red cell distribution width increased, Anisocytosis, Macrocytosis, Elliptocytosis, Confusional state, Pain in extremity, Movement disorder, Polychromic red blood cells present, Neutrophil toxic granulation present, Red blood cell poikilocytes present, Lymphocyte percentage abnormal, Red blood cell count increased, Blood alkaline phosphatase decreased, Vision blurred, Red blood cell count decreased, White blood cell count decreased, Blood creatinine abnormal, Blood urea abnormal, Aspartate aminotransferase increased, Platelet count decreased, Platelet count decreased, Gait disturbance, Visual impairment, Eating disorder, Overweight, Insomnia, Anxiety, Depressed mood, Cytogenetic analysis abnormal, Platelet count increased, Inappropriate schedule of product administration, |
||||
FULVESTRANT, LETROZOLE, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, VISCUM ALBUM FRUITING TOP, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 368 | 26910053 |
US |
1 | |
Hip arthroplasty, Psoriatic arthropathy, Inappropriate schedule of product administration, Therapy interrupted, |
||||
APREMILAST, |
||||
| 369 | 26910087 |
US |
2 | |
Neuralgia, Inappropriate schedule of product administration, |
||||
DUPILUMAB, AMITRIPTYLINE HYDROCHLORIDE, CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE OINTMENT USP, 0.05%, GARLIC, KETOCONAZOLE, KETOCONAZOLE FOAM, KETOCONAZOLE CREAM, 2%, MONTELUKAST SODIUM, MONTELUKAST, MUPIROCIN, MUPIROCIN CALCIUM, NIFEDIPINE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, OXYBUTYNIN CHLORIDE, TAMOXIFEN CITRATE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, ERGOCALCIFEROL, |
||||
| 370 | 26910130 |
CA |
2 | |
Cerebrovascular accident, Fall, Cerebrovascular accident, Pneumonia, Fall, Hypovolaemia, Peripheral swelling, Malaise, Diarrhoea, Abdominal discomfort, Fatigue, Arthropod bite, Joint swelling, Erythema, Nausea, Hypertension, Wrist fracture, Rib fracture, Head injury, Suicide attempt, Bronchitis, Productive cough, Unresponsive to stimuli, Malignant neoplasm progression, Suicidal ideation, Vasculitis, Depression, Depressed mood, Nervousness, Nervousness, Psychiatric symptom, Blood pressure increased, Depression, Tremor, Feeling jittery, Pain in extremity, Wound, Cough, Muscular weakness, Pollakiuria, Nasopharyngitis, Gait disturbance, Hypoacusis, Nervousness, Screaming, Contusion, Emotional distress, Anger, Crying, Mental disorder, Anxiety, Headache, Rash, Feeling abnormal, Inappropriate schedule of product administration, |
||||
AMLODIPINE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, GABAPENTIN, OLANZAPINE, PRUCALOPRIDE SUCCINATE, PREDNISONE, ERGOCALCIFEROL, ESCITALOPRAM, ESCITALOPRAM OXALATE, ESCITSLOPRAM, CALCIUM CARBONATE, ANTACID, PANTOPRAZOLE, |
||||
| 371 | 26910219 |
US |
63 | |
Inappropriate schedule of product administration, Nausea, Asthenia, |
||||
TIRZEPATIDE, |
||||
| 372 | 26910237 |
BR |
2 | |
Suicide attempt, Suicidal ideation, Asthenia, Pain, Feeling abnormal, Headache, Wound, Pruritus, Asphyxia, Neoplasm, Tumour pain, Apathy, Syncope, Swelling, Renal impairment, Cardiac arrest, Eye disorder, Cardiac arrest, Coronavirus infection, Pneumonia, Neoplasm malignant, Cardiomegaly, Neoplasm malignant, Pancreatic enlargement, Abnormal organ growth, Metastatic carcinoid tumour, Throat cancer, Metastasis, Metastasis, Disease recurrence, Metastases to bone, Diabetes mellitus, Arrhythmia, Acromegaly, Bone pain, Visual impairment, Bone marrow infiltration, Nervousness, Malaise, Cataract, Mass, Lung disorder, Bone disorder, Back pain, Agitation, Insomnia, Panic reaction, Feeding disorder, Fear, Fatigue, Stress, Skin hypertrophy, Skin discolouration, Balance disorder, General physical condition abnormal, Hepatomegaly, Crying, Mood altered, Endocrine disorder, Deformity, Dyskinesia, Fall, Foot deformity, Dysphonia, Needle issue, Productive cough, Dyspnoea, Influenza like illness, Headache, Oropharyngeal pain, Incorrect dose administered, Product quality issue, Product storage error, Product physical issue, Inappropriate schedule of product administration, Muscular weakness, Myalgia, Coating in mouth, Hormone level abnormal, Therapeutic product effect delayed, Dyspnoea, Cardiac disorder, Tongue disorder, Liver disorder, Pancreatic disorder, Gallbladder disorder, Headache, Vomiting, Injection site pain, Decreased appetite, Bacteroides test positive, Head injury, Malaise, Retching, Cyanosis, Cardiac valve disease, Asthenia, Sluggishness, Platelet count decreased, Decreased immune responsiveness, Haemangioma of bone, Neuralgia, Anxiety, Gait disturbance, Malaise, Pyrexia, Yellow skin, Skin discolouration, Gait disturbance, Laziness, |
||||
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, SERTRALINE, CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE, CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE, FLUOXETINE HYDROCHLORIDE, FLUOXETINE, |
||||
| 373 | 26910332 |
US |
65 | 1 |
Diabetes mellitus, Inappropriate schedule of product administration, |
||||
EVOLOCUMAB, |
||||
| 374 | 26910388 |
NZ |
39 | 2 |
Suicidal ideation, Anhedonia, Product use in unapproved indication, Product use issue, Inappropriate schedule of product administration, |
||||
| 375 | 26910550 |
US |
1 | |
Foot fracture, Gait inability, Inappropriate schedule of product administration, |
||||
INSULIN GLARGINE, |
||||
| 376 | 26910573 |
US |
||
Pain, Inappropriate schedule of product administration, |
||||
BUROSUMAB, |
||||
| 377 | 26910780 |
EU |
59 | 2 |
Renal impairment, Inappropriate schedule of product administration, |
||||
DENOSUMAB, SOTORASIB, |
||||
| 378 | 26910822 |
US |
67 | 2 |
Inappropriate schedule of product administration, Product storage issue, |
||||
INSULIN GLARGINE, |
||||
| 379 | 26910833 |
US |
2 | 1 |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 380 | 26910874 |
US |
87 | 2 |
Oxygen saturation decreased, Dry eye, Eye irritation, Inappropriate schedule of product administration, |
||||
ACOLTREMON, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, TORSEMIDE, ESCITALOPRAM, SACUBITRIL AND VALSARTAN, ROSUVASTATIN, |
||||
| 381 | 26910981 |
US |
2 | |
Inappropriate schedule of product administration, |
||||
NICOTINE POLACRILEX, NICOTINE, NICOTINE POLACRILEX MINI, NICOTINE POLARILEX, NICOTINE POLACRILEX, NICOTINE, NICOTINE POLACRILEX MINI, NICOTINE POLARILEX, |
||||
| 382 | 26911019 |
GB |
41 | 2 |
Pruritus, Petechiae, Urticaria, Rash pruritic, Inappropriate schedule of product administration, |
||||
ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, PROGESTERONE, PROGESTERONE, IODINE, |
||||
| 383 | 26911024 |
GB |
1 | |
Psoriatic arthropathy, Product supply issue, Inappropriate schedule of product administration, |
||||
USTEKINUMAB, |
||||
| 384 | 26911232 |
US |
74 | |
Urinary tract discomfort, Inappropriate schedule of product administration, |
||||
MITOMYCIN, MITOMYCIN, MITOMYCIN, MITOMYCIN, MITOMYCIN, |
||||
| 385 | 26911241 |
US |
65 | 2 |
Hypertensive crisis, Inappropriate schedule of product administration, Nausea, Blood pressure abnormal, |
||||
TELMISARTAN, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, |
||||
| 386 | 26911530 |
US |
1 | |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 387 | 26912336 |
US |
60 | 2 |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 388 | 26912450 |
EU |
56 | 1 |
Acute psychosis, Inappropriate schedule of product administration, |
||||
TEZEPELUMAB-EKKO, TEZEPELUMAB-EKKO, BECLOMETHASONE DIPROPIONATE/FORMOTEROL FUMARATE/GLYCOPYRROLATE, MOMETASONE FUROATE, MOMETASONE, |
||||
| 389 | 26912587 |
CA |
69 | 2 |
Blood pressure increased, Dyspnoea, Joint swelling, Tooth infection, Nasopharyngitis, Loss of therapeutic response, Anxiety, Inflammation, Malaise, Product ineffective for unapproved use, Off label use, Inappropriate schedule of product administration, Intentional dose omission, |
||||
ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, INFLIXIMAB, INFLIXIMAB, FINERENONE, |
||||
| 390 | 26912629 |
CA |
3 | 2 |
Hospitalisation, Inappropriate schedule of product administration, Product communication issue, |
||||
| 391 | 26912766 |
CN |
81 | 2 |
Alanine aminotransferase increased, Aspartate aminotransferase increased, Hepatic function abnormal, Inappropriate schedule of product administration, |
||||
NIRMATRELVIR AND RITONAVIR, |
||||
| 392 | 26913066 |
TR |
||
Thrombocytopenia, Inappropriate schedule of product administration, |
||||
RAVULIZUMAB, RAVULIZUMAB, |
||||
| 393 | 26913193 |
CA |
36 | 2 |
Injection site erythema, Musculoskeletal stiffness, Inappropriate schedule of product administration, Nasopharyngitis, Injection site pruritus, Arthralgia, |
||||
CERTOLIZUMAB PEGOL, |
||||
| 394 | 26913199 |
47 | 2 | |
Metastases to liver, Metastases to lung, Renal impairment, Palmar-plantar erythrodysaesthesia syndrome, Malnutrition, Adverse event, Adverse reaction, Inappropriate schedule of product administration, |
||||
REGORAFENIB, |
||||
| 395 | 26913318 |
US |
39 | 2 |
Inappropriate schedule of product administration, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 396 | 26913330 |
US |
89 | 1 |
Inappropriate schedule of product administration, |
||||
INSULIN GLARGINE, INSULIN ASPART, |
||||
| 397 | 26913417 |
US |
2 | |
Feeling abnormal, Inappropriate schedule of product administration, |
||||
TIRZEPATIDE, |
||||
| 398 | 26913537 |
BR |
1 | |
Ankylosing spondylitis, Haemorrhoids, Influenza, Memory impairment, Inappropriate schedule of product administration, |
||||
INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, |
||||
| 399 | 26913836 |
US |
46 | 2 |
Stress, Injection site erythema, Inappropriate schedule of product administration, |
||||
SIBEPRENLIMAB, |
||||
| 400 | 26913885 |
US |
62 | 2 |
Headache, Inappropriate schedule of product administration, |
||||
SIBEPRENLIMAB, SIBEPRENLIMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30